In spine, measuring the pressure or load on damaged discs can be an important diagnostic, claims OrthoMEMS, every bit as valuable as current diagnostic techniques that look only at anatomical images. Indeed, OrthoeMEMS believes it has hit upon a fundamentally important new diagnostic tool for spine surgeons, one that offers an objective alternative to current subective diagnoses and that could do for spine and orthopedics what blood pressure management did for general medicine or EKGs for cardiology.
by David Cassak
For nearly a decade, one of the hottest topics in medical devices has been drug/device convergence: combining in a single...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
